1. Among the oral mesalamine delivery systems, one uses ethylcellulose-coated microspheres that release drug continuously beginning in the duodenum and continuing throughout the small bowel and colon, making it the formulation best suited to small bowel Crohn's disease. Which formulation is being described?
A) Asacol HD, a pH-dependent enteric-coated tablet releasing at pH 7.0
B) Pentasa, an ethylcellulose-coated controlled-release granule preparation
C) Lialda, a multi-matrix (MMX) once-daily colonic-release tablet
D) A mesalamine suppository delivering drug to the rectum and distal colon
E) Sulfasalazine, an azo-bonded prodrug cleaved by colonic bacteria
ANSWER: B
Rationale:
Pentasa uses ethylcellulose-coated microspheres (controlled-release granules) that begin releasing mesalamine in the duodenum and continue releasing it continuously throughout the small intestine and colon. This proximal-to-distal continuous release is what makes Pentasa uniquely suited to small bowel Crohn's disease, where disease may lie well above the colon.
Option A: Option A is incorrect: Asacol HD is a pH-dependent enteric-coated tablet that releases at pH 7.0, targeting the terminal ileum and proximal colon—not a continuous small-bowel release system.
Option C: Option C is incorrect: Lialda uses multi-matrix (MMX) technology for slow, extended release throughout the colon from a once-daily tablet, optimized for colonic (not small bowel) delivery.
Option D: Option D is incorrect: a suppository delivers drug only to the rectum and distal 10 to 15 cm, the opposite of broad small-bowel coverage.
Option E: Option E is incorrect: sulfasalazine is an azo-bonded prodrug requiring colonic bacterial cleavage, so its active moiety is released in the colon, not continuously from the duodenum onward.
2. pH-dependent mesalamine formulations rely on enteric polymer coatings that dissolve only once luminal pH rises above a set threshold. Which statement most precisely distinguishes the two Eudragit coating types used for this purpose?
A) Eudragit L and Eudragit S both dissolve in the stomach at acidic pH, releasing drug before the small intestine
B) Eudragit L dissolves at pH 7.0 in the terminal ileum, whereas Eudragit S dissolves at pH 6.0 in the proximal jejunum
C) Neither coating is pH dependent; both rely on colonic bacterial enzymes for dissolution
D) Eudragit L dissolves at the lower threshold (about pH 6.0), releasing more proximally, whereas Eudragit S dissolves at the higher threshold (about pH 7.0), releasing more distally
E) Both coatings dissolve at identical pH, and the difference between them is purely in tablet size
ANSWER: D
Rationale:
The two methacrylate copolymer coatings differ in the pH at which they dissolve, and that threshold determines where in the gut the drug is released. Eudragit L dissolves at the lower threshold of about pH 6.0, releasing mesalamine more proximally (distal small intestine), while Eudragit S dissolves at the higher threshold of about pH 7.0, releasing it more distally (terminal ileum and proximal colon). Because luminal pH rises along the gastrointestinal tract, a higher dissolution threshold corresponds to a more distal release site.
Option A: Option A is incorrect: enteric coatings are specifically designed to resist gastric acid and remain intact in the stomach, releasing only after pH rises in the intestine.
Option B: Option B is incorrect: it reverses the thresholds and sites—Eudragit L is the lower-pH (more proximal) coating and Eudragit S is the higher-pH (more distal) coating.
Option C: Option C is incorrect: these are pH-dependent coatings, distinct from azo-bonded prodrugs that depend on bacterial cleavage.
Option E: Option E is incorrect: the coatings differ in dissolution pH, not merely in tablet dimensions.
3. Olsalazine and balsalazide are both azo-linked mesalamine prodrugs cleaved by colonic bacteria, but they differ in molecular construction and in a characteristic adverse effect. Which statement correctly distinguishes them?
A) Olsalazine is a dimer of two 5-aminosalicylic acid (5-ASA) molecules and is notably limited by dose-dependent secretory diarrhea, whereas balsalazide links 5-ASA to an inert carrier and is generally well tolerated
B) Olsalazine links 5-ASA to sulfapyridine, whereas balsalazide is a dimer of two 5-ASA molecules
C) Balsalazide is a dimer of two 5-ASA molecules causing secretory diarrhea, whereas olsalazine links 5-ASA to an inert carrier
D) Both are dimers of two 5-ASA molecules and neither has any characteristic adverse effect
E) Both link 5-ASA to sulfapyridine and share the full adverse-effect profile of sulfasalazine
ANSWER: A
Rationale:
Olsalazine is an azo-bonded dimer of two 5-ASA molecules; once colonic bacteria cleave the bond, two active mesalamine moieties are released. Its principal limitation is dose-dependent secretory diarrhea, caused by stimulation of intestinal fluid secretion. Balsalazide links one 5-ASA molecule to an inert carrier (4-aminobenzoyl-beta-alanine) that has no pharmacologic activity, and it is generally better tolerated than sulfasalazine.
Option B: Option B is incorrect: neither olsalazine nor balsalazide uses sulfapyridine as a carrier—avoiding sulfapyridine is precisely the point of these sulfa-free agents.
Option C: Option C is incorrect: it reverses the two drugs; olsalazine is the dimer associated with secretory diarrhea, and balsalazide is the inert-carrier compound.
Option D: Option D is incorrect: only olsalazine is a 5-ASA dimer, and it does have a characteristic adverse effect (secretory diarrhea).
Option E: Option E is incorrect: these agents were developed specifically to avoid the sulfapyridine carrier and its sulfasalazine-type toxicity.
4. Sulfasalazine adverse effects vary between patients according to an inherited difference in how one of its components is metabolized. Which statement most precisely identifies the component, the metabolic step, and the at-risk phenotype?
A) The 5-aminosalicylic acid moiety is oxidized by CYP3A4, and rapid oxidizers accumulate toxic metabolites
B) The 5-aminosalicylic acid moiety is glucuronidated, and slow conjugators experience more toxicity
C) The sulfapyridine carrier is acetylated by hepatic N-acetyltransferase, and slow acetylators accumulate higher sulfapyridine concentrations and experience more adverse effects
D) The sulfapyridine carrier is acetylated, and rapid acetylators accumulate higher concentrations and experience more adverse effects
E) The azo bond is hydrolyzed in the liver, and patients with high hydrolase activity experience more adverse effects
ANSWER: C
Rationale:
After colonic bacteria cleave sulfasalazine, the released sulfapyridine carrier is absorbed and acetylated in the liver by N-acetyltransferase. Acetylator status is genetically determined: slow acetylators clear sulfapyridine less efficiently, accumulate higher plasma concentrations, and therefore experience more of the sulfapyridine-attributable adverse effects (nausea, headache, and others).
Option A: Option A is incorrect: the adverse effects track with sulfapyridine metabolism, not with CYP3A4 oxidation of the 5-ASA moiety, and 5-ASA is the comparatively well-tolerated active component.
Option B: Option B is incorrect: the relevant polymorphic step is acetylation of sulfapyridine, not glucuronidation of 5-ASA.
Option D: Option D is incorrect: it inverts the phenotype—slow acetylators, not rapid acetylators, accumulate sulfapyridine and have more toxicity.
Option E: Option E is incorrect: the azo bond is cleaved by bacterial azo-reductase in the colon, not by hepatic hydrolysis, and azo-bond cleavage is the activation step rather than the determinant of sulfapyridine toxicity.
5. Several inflammatory bowel disease drugs converge on inflammatory signaling but through distinct molecular targets. Which pairing correctly matches mesalamine to its mechanism while distinguishing it from a corticosteroid?
A) Mesalamine binds a glucocorticoid-receptor complex to glucocorticoid response elements; corticosteroids inhibit cyclo-oxygenase locally
B) Mesalamine neutralizes tumor necrosis factor-alpha; corticosteroids inhibit dihydrofolate reductase
C) Mesalamine incorporates thioguanine nucleotides into DNA; corticosteroids raise extracellular adenosine
D) Both mesalamine and corticosteroids act primarily by binding glucocorticoid response elements
E) Mesalamine acts locally by inhibiting cyclo-oxygenase and suppressing nuclear factor kappa B (NF-kB) signaling; corticosteroids act by a glucocorticoid-receptor complex binding glucocorticoid response elements to alter gene transcription
ANSWER: E
Rationale:
Mesalamine works topically at the mucosa: it inhibits cyclo-oxygenase (COX), reducing prostaglandin synthesis, and suppresses activation of the transcription factor NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells), lowering pro-inflammatory cytokine output, while also scavenging reactive oxygen species. Corticosteroids work through a different genomic route: the glucocorticoid-receptor complex binds glucocorticoid response elements in gene promoters and transrepresses NF-kB and AP-1, broadly altering gene transcription.
Option A: Option A is incorrect: it swaps the two mechanisms—the glucocorticoid-response-element route is the corticosteroid mechanism, not mesalamine's.
Option B: Option B is incorrect: TNF-alpha neutralization is the action of anti-TNF biologics, and dihydrofolate reductase inhibition is methotrexate's mechanism—neither belongs to mesalamine or corticosteroids here.
Option C: Option C is incorrect: DNA incorporation of thioguanine nucleotides is the thiopurine mechanism, and adenosine elevation is methotrexate's low-dose anti-inflammatory mechanism.
Option D: Option D is incorrect: only corticosteroids act through glucocorticoid response elements; mesalamine does not.
6. A precise distinction between oral budesonide and oral prednisone lies in their systemic bioavailability and the reason for the difference. Which statement states this distinction correctly?
A) Budesonide has roughly 80 to 100 percent oral bioavailability, similar to prednisone, and both cause equal systemic toxicity
B) Budesonide has only about 10 to 15 percent oral systemic bioavailability because of extensive first-pass hepatic metabolism by CYP3A4, whereas prednisone has roughly 80 to 100 percent bioavailability
C) Budesonide has higher systemic bioavailability than prednisone, explaining its greater systemic adverse-effect burden
D) Prednisone has only about 10 to 15 percent bioavailability owing to first-pass metabolism, whereas budesonide approaches 100 percent
E) Neither drug undergoes first-pass metabolism, so their bioavailabilities are identical
ANSWER: B
Rationale:
Budesonide is well absorbed but undergoes extensive first-pass metabolism in the liver, predominantly by CYP3A4 (cytochrome P450 3A4), giving an oral systemic bioavailability of only about 10 to 15 percent. Prednisone, by contrast, has high oral bioavailability (roughly 80 to 100 percent). This large difference is exactly why budesonide produces fewer systemic corticosteroid effects despite high local potency.
Option A: Option A is incorrect: budesonide's bioavailability is low (10 to 15 percent), not comparable to prednisone, and its systemic toxicity is correspondingly lower, not equal.
Option C: Option C is incorrect: budesonide has lower, not higher, systemic bioavailability, which is the basis of its better systemic safety profile.
Option D: Option D is incorrect: it reverses the two drugs—prednisone is the high-bioavailability agent and budesonide is the low-bioavailability agent.
Option E: Option E is incorrect: budesonide specifically undergoes extensive first-pass metabolism, so the two bioavailabilities are far from identical.
7. Budesonide is formulated for different release sites, and the choice of formulation determines which disease distribution it can treat. Which statement correctly distinguishes the ileal-release formulation from the colonic formulation?
A) The ileal-release formulation is effective throughout the entire colon because budesonide is absorbed only after reaching the rectum
B) Both formulations release budesonide identically, so either may be used for any disease location
C) The ileal-release formulation is preferred for extensive colonic disease, whereas the colonic formulation is reserved for the terminal ileum
D) The ileal-release formulation releases and is absorbed in the terminal ileum and is therefore ineffective for colonic Crohn's disease, so a colon-specific (multi-matrix) formulation is required for colonic disease
E) Neither formulation can treat ileal disease, so systemic prednisone is always required
ANSWER: D
Rationale:
Controlled-ileal-release budesonide releases and is largely absorbed in the terminal ileum, which makes it well suited to ileocecal Crohn's disease but ineffective for disease located more distally in the colon—the drug is gone before it reaches colonic mucosa. For colonic involvement, a colon-specific multi-matrix (MMX) budesonide formulation is required so that active drug reaches the colon.
Option A: Option A is incorrect: ileal-release budesonide is absorbed proximally in the terminal ileum, not after reaching the rectum, so it does not treat the whole colon.
Option B: Option B is incorrect: the two formulations differ precisely in release site, so they are not interchangeable across disease locations.
Option C: Option C is incorrect: it reverses the indications—the ileal-release form suits ileal disease, and the colonic form suits colonic disease.
Option E: Option E is incorrect: ileal-release budesonide does treat ileal disease effectively, so prednisone is not mandatory for ileal involvement.
8. In severe acute ulcerative colitis requiring intravenous corticosteroids, both the standard agents and the timing of the response assessment are well defined. Which statement correctly identifies both?
A) Standard agents are intravenous hydrocortisone (about 300 mg/day in divided doses) or methylprednisolone (about 40 to 60 mg/day), with formal response assessment at day 3 and rescue therapy considered if there is no response
B) The standard agent is intravenous dexamethasone 0.5 mg/day, with response assessed only after 14 days
C) The standard approach is intravenous adrenocorticotropic hormone (ACTH) infusion, with no defined assessment interval
D) The standard agent is oral budesonide 9 mg/day, with response assessed at 6 weeks
E) The standard agents are intravenous hydrocortisone or methylprednisolone, but response should not be assessed until at least day 14 to avoid premature escalation
ANSWER: A
Rationale:
For severe acute ulcerative colitis, the standard intravenous corticosteroids are hydrocortisone about 300 mg/day in divided doses or methylprednisolone about 40 to 60 mg/day. Response is assessed formally at day 3 using validated clinical indices; patients without meaningful response should be considered for rescue therapy (infliximab or intravenous cyclosporine) rather than continuing ineffective steroids beyond roughly 5 to 7 days.
Option B: Option B is incorrect: dexamethasone at that dose and a 14-day-only assessment are not the standard approach; the day-3 checkpoint is central to avoiding delayed escalation.
Option C: Option C is incorrect: ACTH has largely been abandoned in favor of direct corticosteroid administration and lacks the defined day-3 framework.
Option D: Option D is incorrect: oral budesonide is a topically acting agent for mild to moderate disease, not the treatment for severe acute colitis, and a 6-week assessment would dangerously delay escalation.
Option E: Option E is incorrect: although the agents are correct, delaying assessment to day 14 contradicts the day-3 decision point that prevents prolonged ineffective steroid exposure.
9. Azathioprine and 6-mercaptopurine are related thiopurines, and the relationship between them is defined by a specific first conversion step. Which statement most precisely describes it?
A) 6-Mercaptopurine is a prodrug converted by hepatic CYP3A4 to azathioprine, the active species
B) Azathioprine and 6-mercaptopurine are unrelated drugs with no metabolic conversion between them
C) Azathioprine is a prodrug that is converted non-enzymatically to 6-mercaptopurine in erythrocytes and intestinal cells, after which 6-mercaptopurine enters its competing metabolic pathways
D) Azathioprine is converted to 6-mercaptopurine exclusively by thiopurine S-methyltransferase before any other metabolism occurs
E) Azathioprine is converted to 6-mercaptopurine only by colonic bacterial azo-reductase, paralleling sulfasalazine activation
ANSWER: C
Rationale:
Azathioprine (AZA) is a prodrug of 6-mercaptopurine (6-MP). The first step is a non-enzymatic conversion of AZA to 6-MP that occurs in erythrocytes and intestinal cells; only afterward does 6-MP enter its three competing enzymatic pathways (HPRT to active 6-thioguanine nucleotides, xanthine oxidase to inactive thiouric acid, and thiopurine S-methyltransferase to inactive 6-methylmercaptopurine).
Option A: Option A is incorrect: it reverses the relationship—azathioprine is the prodrug of 6-mercaptopurine, not the other way around, and CYP3A4 is not the activating route.
Option B: Option B is incorrect: the two drugs are directly related, with azathioprine serving as a prodrug of 6-mercaptopurine.
Option D: Option D is incorrect: the initial AZA-to-6-MP step is non-enzymatic; TPMT acts later and on 6-MP, producing an inactive methylated metabolite.
Option E: Option E is incorrect: bacterial azo-reductase cleavage is the activation route for azo-bonded 5-ASA prodrugs such as sulfasalazine, not for azathioprine.
10. 6-Mercaptopurine is handled by three competing enzymes, each yielding a different metabolite with a different consequence. Which option correctly matches all three enzymes to their products and significance?
A) HPRT yields inactive thiouric acid; xanthine oxidase yields active 6-thioguanine nucleotides; TPMT yields 6-methylmercaptopurine
B) Xanthine oxidase yields active 6-thioguanine nucleotides; HPRT yields 6-methylmercaptopurine; TPMT yields thiouric acid
C) TPMT yields active 6-thioguanine nucleotides; HPRT yields thiouric acid; xanthine oxidase yields 6-methylmercaptopurine
D) All three enzymes yield active 6-thioguanine nucleotides, differing only in rate
E) HPRT yields active 6-thioguanine nucleotides (the immunosuppressive metabolites); xanthine oxidase yields inactive thiouric acid; TPMT yields inactive 6-methylmercaptopurine, which is associated with hepatotoxicity at high levels
ANSWER: E
Rationale:
The three pathways are distinct in product and meaning. HPRT (hypoxanthine-guanine phosphoribosyltransferase) anabolizes 6-mercaptopurine to active 6-thioguanine nucleotides (6-TGN), the immunosuppressive metabolites incorporated into lymphocyte DNA. Xanthine oxidase (XO) catabolizes 6-mercaptopurine to inactive 6-thiouric acid. TPMT (thiopurine S-methyltransferase) produces inactive 6-methylmercaptopurine (6-MMP), which does not accumulate in marrow but is associated with hepatotoxicity at high concentrations.
Option A: Option A is incorrect: it swaps HPRT and xanthine oxidase products—HPRT makes the active metabolite and xanthine oxidase makes inactive thiouric acid.
Option B: Option B is incorrect: xanthine oxidase does not make the active 6-TGN, and HPRT does not make 6-MMP.
Option C: Option C is incorrect: TPMT makes inactive 6-MMP, not the active 6-TGN, and HPRT makes the active metabolite rather than thiouric acid.
Option D: Option D is incorrect: only the HPRT pathway yields the active 6-TGN; the other two yield inactive metabolites.
11. TPMT and NUDT15 both predict thiopurine myelotoxicity, but they are distinct in enzyme function and population epidemiology. Which statement draws the distinction correctly?
A) TPMT methylates 6-mercaptopurine to an inactive metabolite, so loss of activity raises active 6-thioguanine nucleotide levels; NUDT15 is a separate diphosphatase that inactivates thioguanine triphosphates, and its loss-of-function variants (more common in East Asians) cause myelosuppression independent of TPMT
B) TPMT and NUDT15 are two names for the same enzyme, so testing either one alone is sufficient
C) NUDT15 methylates 6-mercaptopurine while TPMT inactivates thioguanine triphosphates, the reverse of their actual functions
D) TPMT loss-of-function is more common in East Asians, whereas NUDT15 variants are essentially confined to Europeans
E) Neither enzyme affects thiopurine metabolite levels; both are markers of drug absorption only
ANSWER: A
Rationale:
TPMT (thiopurine S-methyltransferase) methylates 6-mercaptopurine to inactive 6-methylmercaptopurine; when TPMT activity is low, more 6-mercaptopurine is shunted toward active 6-thioguanine nucleotides, raising myelotoxicity risk. NUDT15 (nudix hydrolase 15) is a separate diphosphatase that inactivates thiopurine triphosphate metabolites; loss-of-function NUDT15 variants let thioguanine triphosphates accumulate and cause myelosuppression even when TPMT is normal. NUDT15 loss-of-function variants are substantially more common in East Asian populations, which is why both enzymes are tested before thiopurine therapy.
Option B: Option B is incorrect: TPMT and NUDT15 are different enzymes with different mechanisms, so testing only one is insufficient.
Option C: Option C is incorrect: it reverses their functions—TPMT is the methyltransferase and NUDT15 is the diphosphatase.
Option D: Option D is incorrect: it inverts the epidemiology—NUDT15 loss-of-function variants are more frequent in East Asians, not confined to Europeans.
Option E: Option E is incorrect: both enzymes strongly influence active metabolite levels and myelotoxicity, not drug absorption.
12. Therapeutic drug monitoring of thiopurine metabolites can reveal a metabolite pattern called preferential methylation. Which statement correctly defines this pattern and its significance?
A) Low 6-methylmercaptopurine with high 6-thioguanine nucleotides, indicating ideal dosing requiring no change
B) Equal 6-methylmercaptopurine and 6-thioguanine nucleotide levels, indicating non-adherence
C) Undetectable levels of both metabolites, indicating rapid renal clearance
D) High 6-methylmercaptopurine with low 6-thioguanine nucleotides, associated with hepatotoxicity and therapeutic failure despite adequate dosing, and sometimes correctable by adding low-dose allopurinol with a reduction of the thiopurine dose
E) High 6-thioguanine nucleotides with undetectable 6-methylmercaptopurine, indicating a poor metabolizer at risk of hepatotoxicity
ANSWER: D
Rationale:
Preferential methylation is the pattern of high 6-methylmercaptopurine (6-MMP) together with low 6-thioguanine nucleotides (6-TGN). It is associated with hepatotoxicity (from high 6-MMP) and with therapeutic failure despite adequate dosing (because the active 6-TGN remains low). The pattern can sometimes be corrected by adding low-dose allopurinol, which inhibits xanthine oxidase and shifts metabolism toward the 6-TGN pathway—but this requires reducing the thiopurine dose to roughly 25 to 33 percent and intensifying blood-count monitoring to avoid 6-TGN toxicity.
Option A: Option A is incorrect: it describes the opposite, favorable pattern, not preferential methylation.
Option B: Option B is incorrect: equal levels are not the defining feature, and non-adherence typically produces uniformly low metabolites.
Option C: Option C is incorrect: undetectable metabolites suggest non-adherence or non-absorption, not preferential methylation.
Option E: Option E is incorrect: preferential methylation features high 6-MMP with low 6-TGN, not high 6-TGN with absent 6-MMP, so this reverses the pattern.
13. The interaction between allopurinol and thiopurines is defined by a specific enzyme effect and a mandatory dosing consequence. Which statement captures both precisely?
A) Allopurinol induces thiopurine S-methyltransferase, lowering 6-thioguanine nucleotides, so the thiopurine dose must be increased
B) Allopurinol inhibits xanthine oxidase, blocking thiopurine catabolism and shifting metabolism toward 6-thioguanine nucleotide accumulation, so the thiopurine dose must be reduced (to roughly 25 to 33 percent) to avoid severe myelosuppression
C) Allopurinol and thiopurines do not interact, so no dose change is required
D) Allopurinol accelerates renal excretion of 6-thioguanine nucleotides, requiring a higher thiopurine dose
E) Allopurinol inhibits hypoxanthine-guanine phosphoribosyltransferase, preventing formation of active metabolites and causing therapeutic failure
ANSWER: B
Rationale:
Allopurinol inhibits xanthine oxidase (XO), the enzyme that catabolizes 6-mercaptopurine to inactive thiouric acid. With that catabolic exit blocked, more 6-mercaptopurine is driven toward the anabolic pathway, sharply increasing active 6-thioguanine nucleotides (6-TGN) and risking severe, even fatal, myelosuppression. Therefore, when allopurinol is combined with a thiopurine, the thiopurine dose must be reduced to roughly 25 to 33 percent of the original with intensified monitoring.
Option A: Option A is incorrect: allopurinol does not induce TPMT or lower 6-TGN; it raises active metabolite levels, so increasing the dose would be dangerous.
Option C: Option C is incorrect: this is a clinically major, potentially lethal interaction, not a benign one.
Option D: Option D is incorrect: allopurinol does not accelerate 6-TGN excretion; the hazard is accumulation, so a higher dose would worsen toxicity.
Option E: Option E is incorrect: allopurinol inhibits xanthine oxidase, not HPRT, and the result is excess active metabolite rather than therapeutic failure.
14. Methotrexate has two mechanistically distinct actions depending on dose. Which statement correctly distinguishes its high-dose cytotoxic mechanism from its low-dose anti-inflammatory mechanism used in inflammatory bowel disease?
A) Both effects arise solely from dihydrofolate reductase inhibition, differing only in degree
B) The high-dose effect raises extracellular adenosine, while the low-dose effect inhibits dihydrofolate reductase
C) The low-dose anti-inflammatory effect comes from incorporation of methotrexate into DNA, while the high-dose effect raises adenosine
D) Both effects come from neutralization of tumor necrosis factor-alpha
E) The high-dose cytotoxic effect is inhibition of dihydrofolate reductase (depleting tetrahydrofolate for purine and thymidylate synthesis), whereas the low-dose anti-inflammatory effect is accumulation of methotrexate polyglutamates that inhibit AICAR transformylase and raise extracellular adenosine
ANSWER: E
Rationale:
At high (chemotherapeutic) doses, methotrexate inhibits dihydrofolate reductase, depleting tetrahydrofolate needed for purine and thymidylate synthesis—a cytotoxic effect on rapidly dividing cells. At the low weekly doses used in inflammatory bowel disease, the dominant anti-inflammatory mechanism is different: intracellular methotrexate polyglutamates accumulate and inhibit AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) transformylase, increasing extracellular adenosine, which suppresses immune-cell function.
Option A: Option A is incorrect: the two effects are mechanistically distinct, not simply different degrees of dihydrofolate reductase inhibition.
Option B: Option B is incorrect: it reverses the dose relationship—dihydrofolate reductase inhibition dominates at high dose and the adenosine mechanism at low dose.
Option C: Option C is incorrect: methotrexate is not incorporated into DNA the way thiopurine metabolites are; the low-dose effect is adenosine-mediated.
Option D: Option D is incorrect: methotrexate does not act by neutralizing TNF-alpha, which is the mechanism of anti-TNF biologics.
15. The preference for parenteral over oral methotrexate in Crohn's disease rests on a specific absorption characteristic. Which statement identifies it most precisely?
A) Oral methotrexate is completely unabsorbed at any dose, so only injection delivers drug
B) Oral methotrexate has perfectly predictable 100 percent bioavailability, and parenteral dosing is merely a matter of convenience
C) Oral methotrexate absorption occurs through a saturable folate carrier transporter, so bioavailability is variable and declines at doses above about 15 mg; parenteral administration bypasses this step and gives reliable systemic exposure
D) Oral methotrexate is inactivated by gastric acid, and parenteral dosing simply avoids the stomach
E) Parenteral methotrexate is preferred because the oral form cannot enter cells, unlike the injected form
ANSWER: C
Rationale:
Oral methotrexate is absorbed via a saturable folate carrier transporter (the reduced folate carrier). Because the transporter saturates, oral bioavailability is variable and falls substantially at doses above roughly 15 mg. Parenteral administration (subcutaneous or intramuscular) bypasses this saturable absorption step, providing reliable and consistently high systemic exposure at the 15 to 25 mg weekly doses used in Crohn's disease.
Option A: Option A is incorrect: oral methotrexate is absorbed, just variably; it is not completely unabsorbed.
Option B: Option B is incorrect: oral bioavailability is variable (roughly 25 to 100 percent), not a predictable 100 percent, so the parenteral preference is pharmacologic, not merely convenience.
Option D: Option D is incorrect: the limitation is saturable carrier-mediated absorption, not gastric acid inactivation.
Option E: Option E is incorrect: methotrexate enters cells by carrier transport regardless of administration route, so the preference reflects absorption reliability rather than an inability of oral drug to enter cells.
16. Methotrexate and thiopurines occupy different positions in ulcerative colitis versus Crohn's disease maintenance. Which statement states the comparative positioning correctly?
A) Methotrexate lacks proven efficacy for ulcerative colitis maintenance, so thiopurines are preferred in ulcerative colitis; in Crohn's disease both are acceptable, with methotrexate often favored in men because the thiopurine-associated lymphoma risk is higher in that group
B) Methotrexate is the preferred maintenance agent for ulcerative colitis, and thiopurines are ineffective in ulcerative colitis
C) Thiopurines are ineffective in both ulcerative colitis and Crohn's disease, leaving methotrexate as the only option
D) Methotrexate and thiopurines have identical evidence in ulcerative colitis and Crohn's disease, so disease type never influences the choice
E) Methotrexate is preferred in women of reproductive age because its pregnancy safety profile is superior to that of thiopurines
ANSWER: A
Rationale:
The evidence differs sharply by disease. Randomized trials show methotrexate has no proven benefit over placebo for ulcerative colitis maintenance, so thiopurines are the preferred immunomodulator there. In Crohn's disease, methotrexate and thiopurines have comparable steroid-sparing efficacy, and the choice is shaped by factors including sex—methotrexate is often favored in men because the thiopurine-associated non-Hodgkin lymphoma risk is higher in men.
Option B: Option B is incorrect: it reverses the ulcerative colitis evidence; methotrexate is the weaker agent in ulcerative colitis, and thiopurines are effective there.
Option C: Option C is incorrect: thiopurines are effective maintenance agents in both diseases, not ineffective.
Option D: Option D is incorrect: disease type clearly influences the choice, given methotrexate's lack of proven ulcerative colitis efficacy.
Option E: Option E is incorrect: methotrexate is teratogenic and therefore less preferred—not preferred—in women of reproductive age.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.